Bellerophon Therapeutics Inc
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial f… Read more
Bellerophon Therapeutics Inc (BLPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: -1.701x
Based on the latest financial reports, Bellerophon Therapeutics Inc (BLPH) has a cash flow conversion efficiency ratio of -1.701x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.33 Million) by net assets ($3.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bellerophon Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Bellerophon Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bellerophon Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bellerophon Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PFA Invest Kreditobligationer Fund
CO:PFIKRB
|
N/A |
|
Plastic Omnium
STU:EZM
|
N/A |
|
MEDION
MU:MDN
|
N/A |
|
Sydinvest - Aggressiv Udb
CO:SYVAUA
|
N/A |
|
DAI NIPPON PRINTING
BE:DNP
|
N/A |
|
IHI Corp
BE:IWJ
|
0.265x |
|
UNITED UTILITIES GR
MU:UUEC
|
N/A |
|
IBA (IOB.SG)
STU:IOB
|
N/A |
Annual Cash Flow Conversion Efficiency for Bellerophon Therapeutics Inc (2012–2022)
The table below shows the annual cash flow conversion efficiency of Bellerophon Therapeutics Inc from 2012 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $2.53 Million | $-17.77 Million | -7.013x | -564.33% |
| 2021-12-31 | $21.62 Million | $-22.82 Million | -1.056x | -103.06% |
| 2020-12-31 | $38.25 Million | $-19.88 Million | -0.520x | +85.57% |
| 2019-12-31 | $3.59 Million | $-12.94 Million | -3.602x | +10.35% |
| 2018-12-31 | $3.86 Million | $-15.49 Million | -4.018x | -166.22% |
| 2017-12-31 | $-2.59 Million | $-15.74 Million | 6.068x | +734.25% |
| 2016-12-31 | $17.99 Million | $-17.21 Million | -0.957x | +37.27% |
| 2015-12-31 | $30.34 Million | $-46.26 Million | -1.525x | +50.43% |
| 2014-12-31 | $22.94 Million | $-70.56 Million | -3.076x | -184.59% |
| 2013-12-31 | $-15.74 Million | $-57.23 Million | 3.637x | +11.60% |
| 2012-12-31 | $-11.12 Million | $-36.22 Million | 3.259x | -- |